Riskpilot← Back to searchSign inGet full accessRetiPharma IVS
IVSIn liquidationCVR 37134120Ole Maaløes Vej 3Engineering activities and related technical consultancy · NACE 7112Est. 20153 employees
Revenue 2018
DKK -147K
EBITDA margin
107.7%
Equity ratio
-2.9%
Financial strength
Net profit 2018
DKK -204K
3 employees
| Revenue | DKK -147K | — |
| EBITDA | DKK -158K | — |
| Net profit | DKK -204K | — |
| Total assets | DKK 6,6M | +658235500% |
| Equity | DKK -190K | -19043800% |
| Employees | 3 | — |
Legal name
RetiPharma IVS
CVR number
37134120
Legal form
Iværksætterselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
10. september 2015
Share capital
DKK 6.816
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2018-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 0 | 0 | -147 |
| Staff expenses | -0 | -0 | -11 |
| EBITDA | 0 | 0 | -158 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | 0 | 0 | -158 |
| Net financials | 0 | 0 | -106 |
| Profit before tax | 0 | 0 | -264 |
| Tax | -0 | -0 | -60 |
| Net profit | 0 | 0 | -204 |
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Total assets | 0 | 0 | 6.582 |
| Equity | 0 | 0 | -190 |
| Long-term debt | 0 | 0 | 6.090 |
| Short-term debt | 0 | 0 | 471 |
| Total debt | 0 | 0 | 6.560 |
EBITDA margin
-15835700.0%
This company
15.8%
Market median
-100226049% vs market
20162018
Equity ratio
-2.9%
This company
38.2%
Market median
-108% vs market
20162018
Return on equity
-20387000.0%
This company
18.4%
Market median
-110799013% vs market
20162018
Net profit margin
-20387000.0%
This company
8.1%
Market median
-251691458% vs market
20162018
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20162018
Debt / equity
35.56×
This company
0.62×
Market median
-5635% vs market
20162018
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-09-10 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AR Unofficial title | Unofficial title | 2019 | — | — |
HV Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
LH Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5.0% | 5.0% | 2015 | |
| Individual | 20.0% | 20.0% | 2015 | |
| Individual | 20.0% | 20.0% | 2015 | |
WEXOTEC ApS | Company | 10.0% | 10.0% | 2015 |
| Individual | 20.0% | 20.0% | 2015 | |
| Individual | 5.0% | 5.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RetiPharma IVS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Rubinstein | Unofficial title | 0 companies |
| Henrik Vissing | Chief Executive Officer | 0 companies |
| Line Hartvig | Chief Executive Officer | 0 companies |
| Jørgen Axel Thorball | Board of Directors | 0 companies |
| Morten Albrechtsen | Chairman | 0 companies |
| Casper Tind Hansen | Board of Directors | 0 companies |